Albert Cortés-Bullich

The evolution of hematopoietic cells under cancer therapy

A. Gonzalez-Perez, N. López-Bigas, F. Muiños, 2020, Nature Communications.

Germ line variants in patients with acute myeloid leukemia without a suspicion of hereditary hematologic malignancy syndrome

D. Colomer, M. López-Guerra, I. Gut, 2023, Blood advances.

Venetoclax with hypomethylating agents might lead to eradication of measurable residual disease (MRD) persisting after intensive chemotherapy in acute myeloid leukemia (AML) patients with mutated NPM1 and rearranged CBF.

M. López-Guerra, M. Díaz-Beyá, F. Fernández-Avilés, 2023, Leukemia research.